Genpharmasec Limited disclosed the voting results of its 34th Annual General Meeting held on September 29, 2026. All five resolutions proposed by the Board were passed with overwhelming majority support from shareholders.

The meeting, conducted via Video Conferencing, focused on adopting financial statements for the fiscal year ended March 31, 2026, and securing the reappointment of key leadership. The proceedings were conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sohan Chaturvedi, serving as Whole-Time Director and CFO, was reappointed for a three-year term through a special resolution. He also retired by rotation and was reappointed as a director in his place. The scrutinizer's report confirmed that no invalid votes were recorded across any resolution.

Resolutions passed

The members voted on five key items, covering both ordinary and special business. The audited standalone and consolidated financial statements for FY26 were adopted alongside the Board of Directors' and Auditors' reports. Voting data indicates high participation from public shareholders relative to outstanding shares in specific categories.

Voting details

The e-voting facility remained open from September 26, 2026, to September 28, 2026. Jaymin Modi & Co., Practising Company Secretaries, served as the Scrutinizer to ensure a fair and transparent process. The report noted that votes cast through remote e-voting were unblocked on September 29, 2026, in the presence of two witnesses.

For Resolution 1 (Adoption of Standalone Financial Statements), 20,40,60,255 votes were polled in favour against 11,782 votes against. This represented 99.99% support among valid votes cast. Similarly, for Resolution 2 (Consolidated Financial Statements), 20,40,60,530 votes supported the adoption, with only 11,507 votes opposing it.

The reappointment of Sohan Chaturvedi as a director (Resolution 3) received 20,40,59,030 votes in favour, while 13,007 votes were cast against. The special resolution for his reappointment as Whole-Time Director for three years (Resolution 4) secured 20,40,58,755 votes in favour against 13,282 votes against.

Resolution 5, regarding approval for loans, guarantees, or security under Section 185 of the Companies Act, 2013, witnessed the highest participation in terms of vote count, with 20,40,69,255 votes in favour and only 2,782 votes against.

Meeting proceedings

The meeting commenced at 11:20 am and concluded at 11:31 am with a vote of thanks. Sohan Chaturvedi chaired the session, confirming that the requisite quorum was present in accordance with Section 103 of the Companies Act, 2013. The Company Secretary briefed members on regulatory matters and general instructions pertaining to e-voting.

Voting results pursuant to Regulation 44(3) of the SEBI Listing Regulations have been submitted to BSE Limited. The company confirmed that statutory registers and documents related to ordinary and special business were available for inspection upon request. All notices were sent electronically to members with registered email addresses.

Genpharmasec Limited has submitted its annual report for the financial year 2025-26 to the Bombay Stock Exchange. The filing, dated September 7, 2026, includes the notice for the company's 34th Annual General Meeting.

The submission was made pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sohan Chaturvedi, Whole-time Director and CFO of Genpharmasec Limited, digitally signed the disclosure on behalf of the company.

Filing Details

The company transmitted the annual report electronically to members who have registered email addresses with the firm or its Registrar and Transfer Agent. For shareholders without registered email IDs, the company is sending a letter containing a web link to access the document, in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations.

The annual report and AGM notice are also available on the company's investor relations website. The filing does not disclose specific financial metrics such as revenue, net profit, or dividend declarations in this regulatory communication.